The researchers conducted genome-wide association studies of individuals who reported hearing difficulties and those who used hearing aids.
The UK-based genomic data compression software company has named startup Genique Lifesciences as its exclusive distributor in India.
The organizations noted in a letter to HHS and FDA that they "believe the agency's actions may in fact inflict greater harm on patients and impede innovation."
A report from the NSIGHT2 trial compares the diagnostic and analytical performance of clinical whole-genome and exome sequencing on an infant cohort.
Researchers from Wellcome Sanger Institute and elsewhere found that the immune landscape of the kidney is zoned to counter dominant immunological challenges.
The Broad Institute spinout will develop its CRISPR-based Sherlock platform for battlefield-ready diagnostics for infectious disease agents.
The companies will offer customers a way to mine 23andMe's customer base for subjects with specific genetic or clinical features, and design and conduct a trial around them.
Under the amended agreement, Illumina will pay PacBio $6 million each month until the end of this year and more if the deal is extended into 2020.
CareDx claims that Eurofins Viracor infringes on its patent related to noninvasive monitoring of organ transplant rejection through cell-free DNA analysis.
The company said the money from the transactions will help it boost adoption of its ConfirmMDx and SelectMDx prostate cancer tests with urologists and payors.
The Netherlands-based biotech firm will use the funding to develop a group of biomarkers to detect colorectal cancer.
Researchers also uncovered associations between any psychotic experience and the genetic liability for schizophrenia, major depressive disorder, and bipolar disorder.
The Simplexa VZV Swab Direct runs on the firm's Liason MDX instrument and has also been submitted to the US Food and Drug Administration.
The firm will offer €4.4 billion of euro-denominated notes and $900 million in dollar-denominated notes. It will redeem another $4.5 billion in outstanding notes.
The distributor, Bionuclear Puerto Rico, will give T2 access to approximately 64 hospitals in Puerto Rico and the US Virgin Islands.
The in vitro diagnostic uses next-generation sequencing to detect clinically actionable genetic variants to guide therapy selection for cancer patients.
Using 350 human genomes from different populations, the two centers plan to develop a multi-genome reference sequence that is as complete as possible.
As part of the collaboration, researchers will study exosomes in cancer patients and individuals who have a high genetic risk for cancer.
The companies will use Foundation Medicine's FoundationOne CDx test as the baseline to define a set of unique variants that the codeveloped assays will monitor.
Under the agreement, the companies plan to offer combined genetic and biochemical testing services out of Blueprint's clinical laboratory in Seattle.
CareDx will use NanoString's new Human Organ Transplant panel to develop HistoMap, a gene expression profiling test to identify allograft rejection.
Seattle-based Adaptive will develop in vitro diagnostic test kits for distribution, which will run on Illumina's NextSeq 550 Dx system.
The assay is based on the company's AmpiProbe technology, which uses fluorescent reporter-labeled primers and quencher-labeled primers to amplify DNA.
The analysis further found that the degree of network perturbation correlated with the severity of toddlers' autism spectrum disorder.
Researchers have sequenced the genome of the depth-dwelling giant squid.
Prosecutors have charged a former Drexel University professor with theft for allegedly spending federal grant money on adult entertainment and other unrelated expenses, according to the Philadelphia Inquirer.
Chris Collins, a former US representative, has been sentenced to more than two years in prison in an insider trading case involving an Australian biotechnology firm, the New York Times reports.
In PNAS this week: Trypanosoma brucei transcripts, estimate of people at risk of inherited retinal disease, and more.